The oral-to-intravenous equianalgesic ratio of morphine based on plasma concentrations of morphine and metabolites in advanced cancer patients receiving chronic morphine treatment

Palliative Medicine

Volumn 17, Issue 8, 2003, Pages 673-678

  Takahashi, Masahiko ^a   Ohara, Takeshi ^a   Yamanaka, Hiroyuki ^a   Shimada, Akira ^a   Nakaho, Toshimichi ^a   Yamamuro, Makoto ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Morphine pharmacokinetics; Oral intravenous relative potency ratios for morphine

Indexed keywords

ALBUMIN; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; BIOCHEMICAL MARKER; BISPHOSPHONIC ACID DERIVATIVE; C REACTIVE PROTEIN; CORTICOSTEROID; CREATININE; GLOBULIN; LACTATE DEHYDROGENASE; MORPHINE; MORPHINE 3 GLUCURONIDE; MORPHINE 6 GLUCURONIDE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NITROGEN; NONSTEROID ANTIINFLAMMATORY AGENT; PROTEIN; UREA;

ADULT; ADVANCED CANCER; AGED; ANALGESIA; ARTICLE; CANCER PAIN; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DOSE RESPONSE; DRUG ADMINISTRATION ROUTE; DRUG BLOOD LEVEL; DRUG POTENCY; FEMALE; HOSPITAL PATIENT; HUMAN; INTERMETHOD COMPARISON; LONG TERM CARE; MALE; REGRESSION ANALYSIS; SIDE EFFECT;

ADMINISTRATION, ORAL; AGED; ANALGESICS, OPIOID; CHRONIC DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INFUSIONS, PARENTERAL; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; MORPHINE; MORPHINE DERIVATIVES; NEOPLASMS; PAIN; PALLIATIVE CARE;

EID: 0345099462     PISSN: 02692163     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Zech DFJ, Grond S, Ivyneh J, et al. Validation of World Health Organization Guidelines for cancer pain relief: a 10-year prospective study. Pain 1995; 63: 65-76.
2. Stjernswärd, J Colleau SM. The World Health Organization cancer pain and palliative care program, past, present, and future. J Pain Symptom Manag 1996; 12: 65-72.
3. McQuay H. Opioids in pain management. Lancet 1999; 353: 2229-32.
4. Hanks G, Cherny N. Opioid analgesic therapy. In Doyle D, Hanks GWC, MacDonald N eds. Oxford textbook of palliative medicine, second edition. New York: Oxford University Press, 1998: 331-52.
5. Expert Working Group of the European Association for Palliative Care. Fortnightly Review: morphine in cancer pain: models of administration. BMJ 1996; 312: 823 -26.
6. Mercadante P, Fulfaro F, Casuccio A. Investigation of an opioid response categorization in advanced cancer patients. J Pain Symptom Manag 1999; 18: 347-52.
7. Mercadante S, Casuccio A, Pumo S, et al. Opioid responsiveness-primary diagnosis relationship in advanced cancer patients followed at home. J Pain Symptom Manag 2000; 20: 27-34.
8. Wolff T, Samuelsson H, Hender T. Concentrations of morphine and morphine metabolites in CSF and plasma during continuous subcutaneous morphine administration in cancer pain patients. Pain 1999; 68: 209-16.
9. Vermeire A, Remon JP, Rosseel MT, et al. Variability of morphine disposition during long-term subcutaneous infusion in terminally ill cancer patients. Eur J Clin Pharmacol 1998; 53: 325-30.
10. Schag CC, Heinrich RL, Ganz PA. Karnofsky performance status revisited: reliability, validity, and guidelines. J Clin Oncol 1984; 2: 187-93.
11. Konishi M, Hashimoto H. On-line clean-up system of plasma sample for simultaneous determination of morphine and its metabolites in cancer patients by high-performance liquid chromatography. J Pharmacol Sci 1990; 79: 379-83.
12. Faura CC, Moore RA, Horga JF, et al. Morphine and morphine-6-glucuronide plasma concentrations and effect in cancer pain. J Pain Symptom Manag 1996; 11: 95-102.
13. Hanks GW, Hoskin PJ, Aherne GW, et al. Explanation for potency of repeated oral doses of morphine. Lancet 1987; 26: 723-24.
14. Stain F, Barjavel MJ, Sandouk P, et al. Analgesic response and plasma and brain extracellular fluid pharmacokinetics of morphine and morphine-6-beta-D-glucuronide in the rat. J Pharmacol Exp Ther 1995; 274: 852-57.
15. Krzanowska EK, Rossi GC, Pasternak GW, et al. Potency ratios of morphine and morphine-6 beta-glucuronide analgesia elicited from the periaqueductal gray, locus coeruleus or rostral ventromedial medulla of rats. Brain Res 1998; 799: 329-33.
16. Osborne R, Thompson P, Joel S, et al. The analgesic activity of morphine-6-glucuronide. Br J Clin Pharmacol 1992; 34: 130-38.
17. Penson RT, Joel SP, Bakhshi K, et al. Randomized placebo-controlled trial of the activity of the morphine glucuronides. Clin Pharmacol Ther 2000; 68: 667-76.
18. Mercadante S. The role of morphine glucuronides in cancer pain. Palliat Med 1999; 13: 95-104.
19. Serlin RC, Mendoza TR, Nakamura Y, et al. When is cancer pain mild, moderate or severe? Grading pain severity by its interference with function. Pain 1995; 61: 277-85.
20. Cleeland CS, Nakamura Y, Mendoza TR, et al. Dimensions of the impact of cancer pain in a four country sample: new information from multidimensional scaling. Pain 1996; 67: 267-73.
21. Peterson GM, Randall CTC, Paterson J. Plasma levels of morphine and morphine glucuronides in the treatment of cancer pain: relationship to renal function and route of administration. Eur J Clin Pharmacol 1990; 38: 121-24.
22. Säve J, Svensson JO, Rane A. Morphine metabolism in cancer patients on increasing oral doses - no evidence for autoinduction or dose dependence. Br J Clin Pharmacol 1998; 16: 85-93.
23. Portenoy RK, Foley KM, Stulman J, et al. Plasma morphine and morphine-6-glucuronide during chronic morphine therapy for cancer pain: plasma profiles, steady-state concentrations and the consequences of renal failure. Pain 1991; 47: 13-19.
24. Tiseo PJ, Thaler HT, Lapin J, et al. Morphine-6-glucuronide concentrations and opioid-related side effects: a survey in cancer patients. Pain 1995; 61: 47-54.
25. Patwardhan RV, Johnson RF, Hoyumpa A, et al. Normal metabolism of morphine in cirrhosis. Gastroenterology 1981; 81: 1006-11.
26. Crotty B, Watson KJ, Desmond PV, et al. Hepatic extraction of morphine is impaired in cirrhosis. Eur J Clin Pharmacol 1989; 36: 501-506.